

## Research Report – Update

*Investors should consider this report as only a single factor in making their investment decision.*

### Global WholeHealth Partners Corp.

**Rating: Speculative Buy**

Howard Halpern

December 1, 2020

**GWHP \$1.48 — (OTC)**

|                                 | 2018 A           | 2019 A   | 2020 A                  | 1Q21A    |
|---------------------------------|------------------|----------|-------------------------|----------|
| Revenue (in thousands)          | \$0              | \$0      | \$242                   | \$15     |
| Earnings (loss) per share       | (\$0.02)         | (\$0.01) | (\$0.07)                | (\$0.00) |
| 52-Week range                   | \$14.50 – \$0.40 |          | Fiscal year ends:       | June     |
| Shares outstanding a/o 11/12/20 | 60.0 million     |          | Revenue/shares (ttm)    | NMF      |
| Approximate float               | 28.6 million     |          | Price/Sales (ttm)       | NMF      |
| Market Capitalization           | \$88.8 million   |          | Price/Sales (2021) E    | NA       |
| Tangible Book value/shr         | \$0.00           |          | Price/Earnings (ttm)    | NA       |
| Price/Book                      | NMF              |          | Price/Earnings (2021) E | NA       |

*Global WholeHealth Partners Corp., headquartered in San Clemente, CA, was founded to develop, manufacture and market in-vitro and rapid diagnostic tests. The company's vision is to provide infectious disease diagnostics and molecular solutions that reduce the time to diagnose medical results. The company plans to produce and sell rapid diagnostic tests that include but is not limited to, Corona Viruses including COVID-19, Ebola, ZIKA, Dengue, Malaria, Influenza, and Tuberculosis.*

#### Key Investment Considerations:

*We are maintaining Global WholeHealth Partners with a Speculative Buy rating.*

*Global WholeHealth Partners has an opportunity to penetrate the rapid COVID-19 diagnostic testing market given that it has three COVID-19 diagnostic tests submitted and pending for FDA emergency use approval. Two of the company's tests are a 10 minute rapid diagnostic test that requires no machine, and a global antigen COVID-19 rapid test. GWHP also received authorization to sell tests from Idrop Inc. and Healgen.*

*Our World Data estimates daily US COVID-19 testing hit a peak of 4.55 per 1,000 that equals approximately 1.5 million tests as of November 18, 2020. The rapid COVID-19 testing market is likely to continue growing significantly in order to attempt to contain the fall 2020 and winter 2021 outbreak the US and the rest of the world is currently experiencing. Global Market Insights projects the Global COVID-19 detection kits market could surpass \$8.5 billion by 2026 growing at an annualized rate of 17.3% from 2020.*

*The market potential is substantial given that in September 2020, the US government purchased 150 million COVID-19 tests from one of the largest diagnostic testing companies for \$760 million. Also, In November 2020, the US Food and Drug Administration granted emergency use authorization for a first rapid at-home COVID-19 test (manufactured by Lucira Health), which is a 30-minute prescription-only test. Additional funding for the purchase of rapid COVID-19 tests is likely to occur if Congress passes stimulus packages.*

*In 1Q21 (ended September 30, 2020), GWHP generated revenue of \$15,000 and had a net loss of \$247,000 or breakeven per share. In the year-ago period the company had no revenue and a net loss of \$19,000 or breakeven per share.*

*While the company has the potential to generate significant sales upon receiving FDA authorization for its COVID-19 tests that are under review for emergency use authorization, it is likely GWHP will need additional capital in order to build a commission based distribution network and production of tests.*


**Please view our Disclosures pages 14 - 16**

**Recommendation**

**We are maintaining Global WholeHealth Partners with a Speculative Buy rating.**

Global WholeHealth Partners has an opportunity to penetrate the rapid COVID-19 diagnostic testing market given that it has three COVID-19 diagnostic tests pending FDA emergency use approval. Two of the company’s tests are a 10 minute rapid diagnostic test that requires no machine, and a global antigen COVID-19 rapid test. In September 2020, a third rapid global rapid antigen test was submitted by Charles Strongo (CEO) on behalf of the company for emergency use approval. GWHP also received authorization to sell tests from 1drop Inc. and Healgen.

Our World Data estimates daily US COVID-19 testing hit a peak of 4.55 per 1,000 that equals approximately 1.5 million tests as of November 18, 2020. The rapid COVID-19 testing market is likely to continue growing significantly in order to attempt to contain the late 2020 and early 2021 outbreak the US and the rest of the world is experiencing. Global Market Insights projects the Global COVID-19 detection kits market could surpass \$8.5 billion by 2026 growing at an annualized rate of 17.3% from 2020.




Beyond the COVID-19 testing market, industry reports indicate that the global In-Vitro Diagnostics Market is expected to grow 4.5% annually reaching \$87.1 billion by 2026, up from \$61.2 billion in 2018. Driving market growth is expected to be the increasing demand for self-test and point-of-care devices that should increase the demand for reagents and consumables that are the foundation of the industry.

On June 24, 2020, GWHP stock hit a 52-week high price of \$14.50 when it announced its first application for emergency use authorization under review at the US Food and Drug Administration for the company’s IgM/IgG in-vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in Serum/Plasma and Whole Blood cells of patients exposed to the SARS-CoV-2 virus (COVID-19). Investors are likely to experience share price swings once the company receives emergency use approval from the FDA as well as announcements regarding sales of COVID-19 tests through its 1drop Inc. and Healgen partnerships and limited shipments of its own COVID-19 tests (under the FDA March 16th guideline, which allows tests to be sold once a tests’ accuracy is demonstrated to be 90%+ and a pre-emergency use application has been filed with the FDA).

**We believe Global WholeHealth Partners is most suitable for very high-risk tolerant investors seeking exposure to a micro cap company that is attempting to establish a business within the rapid and in-vitro diagnostic testing market.**

**Overview**

Global WholeHealth Partners Corp., headquartered in San Clemente, CA, was founded to develop, manufacture and market in-vitro and rapid diagnostic tests. The company’s long-term goal is to be a low cost provider of infectious disease diagnostics based on molecular solutions that lessen the time to diagnose medical results, thus empowering healthcare professionals to make accurate decisions for patients in as short a time as possible. The company plans to produce and sell rapid diagnostic tests that include, but is not limited to, Corona Viruses including COVID-19, Ebola, ZIKA, Dengue, Malaria, Influenza, and Tuberculosis (virus’s pictured on the right). As time progresses, the company’s plan is to produce diagnostic tests for over-the-counter, consumer-use, and point-of-care-use for professionals that includes



hospitals, physicians' offices, and medical clinics, including those within penal systems.

The company offers 56 unique FDA approved over-the-counter tests for sale that include pregnancy, cholesterol, glucose, and for various drugs such as amphetamines, barbiturates, benzodiazepine, cocaine, and marijuana. Also, the company offers eight tests that only physicians and medical professionals can administer, which includes Influenza, Fecal Blood, and Strep.

In FY21, GWHP expects to be focused on the production and shipment to customers of its three COVID-19 tests that have been submitted to the FDA for emergency use approval (still under review as of November 30, 2020). In anticipation of receiving emergency use approvals, GWHP will need to be building a distribution network in order to sell its COVID-19 tests to high complexity diagnostic medical labs or medical institutions that qualify under the FDA guidelines, as well as federal, state, and local government agencies in the US and other potential users such as hospitals, schools, non-profit organizations, etc. The magnitude of sales is yet to be determined but could be substantial once approval for its tests are granted and a distribution network begins to sell the company's COVID-19 tests.

### History

In March 2013, Global WholeHealth Partners Corporation was incorporated as Texas Jack Oil and Gas Corp. In May 2019, the company changed its name to Global WholeHealth Partners Corporation (and symbol to GWHP) to align it with its focus on health care related development and products.

On May 9, 2019, a reverse split (1-for-500) of GWHP's outstanding common shares was effective and outstanding shares were reduced to approximately 116,000 from nearly 58.2 million.

On May 23, 2019, Global WholeHealth Partners and LionsGate Funding Group, owner of a majority of the company's outstanding common stock, entered into a stock sale and purchase agreement and the company issued 56 million shares of common stock to LionsGate in exchange for 100% of their interests in Global WholeHealth Partners Corp., a private Wyoming corporation incorporated on April 9, 2019.

In 4Q20 and 1Q21, revenue of \$242,000 and \$15,000 was generated, respectively, which were the first quarterly reported sales in the company's history.

On September 29, 2020, the Company's CEO was also appointed as the company's CFO and Treasurer, upon the resignation of Richard Johnson its prior CFO and Treasurer.

### ***Development of COVID-19 Pandemic Test Portfolio***

In January 2020, in response to the COVID-19 pandemic, Global WholeHealth Partners set out to test and perform studies necessary to develop a rapid diagnostic test and real time polymerase chain reaction test (a test that detects genetic material of a virus using lab techniques). In the quarter ending June 30, 2020 (4Q20), the company completed the testing necessary in order to submit to the FDA two of its COVID-19 tests for emergency use approval. According to public information provided by the company, its rapid diagnostic test results should be available in 10 minutes with an overall accuracy rate of 98%, with its real time polymerase chain reaction (PCR) test, which looks for the E-Gene and RdRq-Gene markers, having an estimated 97% accuracy rate. The test is able to be processed in any FDA approved polymerase chain reaction machine with each of the company's test kits including the required reagents. Global WholeHealth Partners has, and will continue to use, third-party labs for evaluations of its own rapid diagnostic COVID-19 tests.

In March 2020 and April 2020, the company's CEO, Charles Strongo, filed on the behalf of GWHP, a pre-emergency use application with the FDA for its polymerase chain reaction (PCR) test for COVID-19 and for its COVID-19 rapid diagnostic test. The FDA sent an official acknowledgement letter accepting the application for each test. The company is in the process of responding to FDA inquires.


In May 2020, GWHP received a letter of authorization from 1drop Inc. that authorizes GWHP to sell 1drop Inc.'s 1copy™ COVID-19 qPCR Multi Kit. An FDA filing stated the kit received emergency use authorization on May 20, 2020 for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal, oropharyngeal, anterior nasal, mid-turbinate nasal swab specimens, as well as nasopharyngeal wash/aspirate and nasal aspirate specimens collected from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity tests.

On August 3, 2020, the company received a letter of authorization from Healgen Scientific Limited which authorizes GWHP to sell their SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma test. On May 29, 2020, Healgen Scientific Limited received emergency use authorization for its COVID-19 IgG/IgM rapid test cassette from the FDA. According to information from the FDA, this test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

In September 2020, a third rapid global rapid antigen test was submitted by Charles Strongo (CEO) on behalf of the company for emergency use approval.

### **Strategy**

Global WholeHealth Partners mission is to build an integrated organization that can effectively and efficiently control disease outbreaks through testing, while reducing health care costs. Management aims to position the company as a provider of infectious disease diagnostic tests by providing molecular solutions that lessen the time to diagnose medical results. If achieved, this should empower healthcare professionals to make better diagnostic decisions, as well as lowering healthcare costs. The chart on the right highlights (source: company's Website a/o October 1, 2020) what the company believes the rapid and PCR diagnostic tests it has in its product portfolio can achieve within the diagnostic testing market.



Its marketing strategy is to use industry contacts, primarily through government and strategic partners, to establish initial distribution channels in order to gain market penetration. Eventually, the company aims to develop a commission based distribution network of connected customers through online advertising and Webinars.

An early example of its sales strategy occurred in April 2020 when the company announced that the Department of Navy ordered 1,000 rapid diagnostic tests based on the FDA March 16th guideline that allows tests to be sold once a tests accuracy is demonstrated to be 90%+ and a pre-emergency use application has been filed with the FDA while working with the FDA for approval. The NAVY order was delivered on April 29, 2020 at the Navy Base at Point Loma, CA.

### **Industry Briefs**

#### **COVID-19 Testing**

The Business Research Company published a report indicating that the global COVID-19 rapid test kits market should reach over \$4.7 billion in 2023, up from an estimated \$3.5 billion in 2020 for annualized growth of approximately 10.4%. Growth will be driven by sales in the largest market North America followed by countries in the Asia-pacific region. In June 2020, Global Market Insights projected that the Global COVID-19 detection kits market could surpass \$8.5 billion by 2026 growing at an annualized rate of 17.3% from 2020.

In the US Our World Data estimates daily COVID-19 testing hit a peak (on November 18, 2020) of 4.55 per 1,000 or approximately 1.5 million conducted daily. The rapid COVID-19 testing market is likely to continue growing significantly in order to contain current and future outbreaks in the US and the rest of the world.

The COVID-19 rapid testing market is substantial. In September 2020, the US government purchased 150 million rapid COVID-19 tests from one of the largest diagnostic testing companies for approximately \$760 million. In November 2020, the US Food and Drug Administration granted emergency use authorization for a first rapid at-home COVID-19 test (manufactured by Lucira Health), which is a 30-minute prescription-only test.

### **Rapid Diagnostic Test Market**

In August 2020, market research firm Grandview Research published a report that forecast the Global Rapid Medical Diagnostic Kits market to reach at least \$23.2 billion in 2027, up from \$16.7 billion in 2019, as annual growth should approximate 4.2% during the forecast period. Test kits are easy to use and require limited training, facilitating effective analysis since the target population includes the general population suffering from chronic diseases such as cancer, infectious diseases, and diabetes. All of those disease indications are expected to drive industry growth. The rising need and awareness for rapid detection of chronic diseases is also expected to boost the adoption of medical kits especially for point-of-care diagnostics usage. We anticipate the growth could accelerate faster than the report anticipates due primarily to testing needs until the COVID-19 pandemic environment eases. According to Grandview Research, governments are investing heavily to curb the high prevalence of various infectious diseases such as malaria and the novel coronavirus.

### **In-Vitro Diagnostics Market**

The in vitro diagnostic (IVD) market has developed into promising techniques in the field of medical diagnostics. The IVD sector plays a critical role in shifting the healthcare and drug discovery landscape that has the potential to lower costs and increase the accuracy of testing results. IVD tests are performed on tissue, blood, or bodily fluids of a patient to detect and ultimately treat diseases.

According to a report issued by global market research firm Research Dive, the COVID-19 pandemic is driving innovation within the IVD market. Factors driving industry growth include increasing adoption of lab automation, and the presence of a significant number of patients suffering from infectious and chronic disorders. Supportive government policies for in-vitro diagnostics should also assist industry growth. An ongoing example is the COVID-19 pandemic which started in January 2020 and resulted in a domino effect as governments worldwide instituted new emergency use programs to get testing in place as quickly as possible. Those emergency use programs enabled manufacturers to focus on product development related to COVID-19 pandemic tests. A consequence of the programs instituted by governments to speed up the process for getting IVD tests approved is likely to remain in place after the COVID-19 pandemic environment eases.

In August 2020, ResearchAndMarkets.com published a report that projected the global IVD market could reach nearly \$114 billion by 2030, up from an estimated \$69.5 billion in 2020 for annualized growth of 5.1%. Over the forecast period, North America is anticipated to grow annually by at least 4.4%, with the Asia-Pacific region growing by 6.1%, and Europe growing by nearly 5% annually through 2030. In 2019, the largest market was North America, followed by Europe, and Asia.

### **Infectious Disease Diagnostics Market**

In August 2020, ResearchAndMarkets.com published a report that projected the Global Infectious Disease Diagnostics Market to grow annually at a low single digit rate from 2020 to 2027. The report estimated the market reaching approximately \$26 billion by 2027. The primary growth drivers are the increasing need for early detection for infectious disease that should result in increasing usage of point-of-care diagnostics and rapid diagnostics tests, as well as favorable reimbursements and technological advancements through increasing investments.

### **Outlook Potential**

The company's revenue generating potential will be from the company's three rapid diagnostic COVID-19 tests that have been submitted to the FDA for emergency use approval. In 4Q20, the company generated its first revenue of

\$242,000 from initial shipments of its COVID-19 rapid diagnostic test. We believe those test shipments were from the previously announced April 29, 2020 delivery of 1,000 rapid diagnostic tests to a Navy Base at Point Loma, CA, under the FDA March 16th guideline, which allows tests to be sold once its accuracy is demonstrated to be 90%+ and a pre-emergency use application has been filed with the FDA. However, revenue decreased to approximately \$15,000 in 1Q21.

In order for GWHP to generate sustained revenue and revenue growth it will need to build a commission based distribution network that can sell its test to the approximately 260,000 complex clinical medical laboratory entities that are regulated by the Centers for Medicare & Medicaid Services. The company's distribution network will also need to develop contacts to sell the company's offerings to US Federal, state, and local government agencies, as well as other potential users such as corporations, hospitals, schools, non-profit organizations, etc.

While the level of sales is yet to be determined, it could be substantial once the FDA grants final emergency use approvals for its tests. Management anticipates it will eventually generate sales of its rapid diagnostic and polymerase chain reaction tests to domestic and international private and public entities. However, we are refraining from forecasting given the lack of an established distribution network to sell the company's COVID-19 tests.

The company anticipates it could initially have the capacity to support the production of approximately 100,000 rapid COVID-19 tests per month, which could eventually grow to support over 100,000 tests per day.

### ***1Q21 Results***

In 1Q21 (ended September 30, 2020), GWHP reported revenue of approximately \$15,000 with a gross profit of \$5,000 as gross margin was 31.5%. In 1Q20, the company had no revenue or gross profit.

Total operating expenses increased to \$206,000 from nearly \$19,000 in the year-ago period. The increase was due primarily to R&D spending of \$139,000 compared to none in 1Q20 due primarily to study costs related to COVID-19 rapid diagnostic tests the company anticipates selling after receiving FDA approval. Professional fees increased to nearly \$34,000 from nearly \$15,000 in the year-ago period. SG&A costs were \$33,000 compared to \$4,000 in the year-ago period. The increase in professional fees and SG&A costs reflects the company's efforts to advance its COVID-19 tests.

The loss from operations was \$201,000 compared to a loss of nearly \$19,000.

Other expense was nearly \$46,000 compared to none in the year-ago period. In 1Q21, the company incurred interest expense of nearly \$5,000 and accretion of debt discount of \$41,000.

The net loss was \$247,000 or breakeven per share, on average shares outstanding of 60 million compared to a net loss of \$19,000 or breakeven per share on average shares outstanding of 56 million.

### ***Finances***

In 1Q21, the company had cash burn of \$206,000 and an \$89,000 increase in working capital that resulted in cash used in operations of \$295,000. The increase in working capital was due primarily to an increase in inventory. The issuance of convertible notes and common stock covered cash used in operations. Cash increased by approximately \$118,000 to nearly \$133,000 at September 30, 2020.

### ***Capital Structure***

At September 30, 2020 the company had total outstanding debt of \$186,000 from a related party note of nearly \$37,000 and convertible notes of \$149,000.

On March 29, 2020, GWHP issued a promissory note to LionsGate in the amount of \$507,000 that was equivalent to the advances made to the company up to March 29, 2020. On March 30, 2020, LionsGate decided it would be in the best interests to forgive the portion of the note related to testing costs which totaled nearly \$443,000. On September 30, 2020, the note balance was nearly \$37,000, after repayment of approximately \$110,000 during 1Q21. The terms

of the note provided for total funding of up to \$585,000 at a 5% annual interest that matured on June 30, 2020. However, the note was amended to mature on June 30, 2021. If not paid by the maturity date, a 5% penalty will be added to the note and the term will extend for an additional 90 days.

In July/August/September 2020, the company and Geneva Roth Remark Holdings, Inc. entered into separate and identical securities purchase agreements for convertible promissory notes that totaled \$171,000 (principal amount) but received net proceeds that totaled \$162,000 (net of legal fees). At September 30, 2020 the outstanding balance was \$149,000. The convertible notes mature in July/August/September 2021 and accrue interest of 10% and, after 180 days, are convertible into shares of common stock any time at a conversion price equal to 58% of the lowest trading price during the twenty trading day period ending on the latest complete trading day prior to the conversion date. Geneva agreed to restrict its ability to convert the notes so that its equity interest does not exceed 4.99% of the then issued and outstanding shares of common stock. In the event of default, the note interest rate increases to 22%.

In 1Q21, the company received \$340,000 from Dr. Scott Ford, a director of the company in exchange for restricted common stock.

### ***Competitive Landscape***

The diagnostics industry is very competitive and is in transition during the COVID-19 pandemic environment. The industry has and is continuing to experience consolidation through mergers and acquisitions. The consolidation trend is likely to result in companies having greater financial resources and technological capabilities, thereby intensifying competition in the industry. The competitive factors affecting the sale of diagnostic products are typically uniqueness, technology, product reliability, performance, price, service and marketing.

Some of the companies that compete in the industry include Abbott Diagnostics, Arkray, Bio-Rad, Diasorin Inc., Johnson & Johnson, OraSure Technologies Inc., Roche Diagnostics, Siemens, Thermo Fisher, and Tosoh. Some more direct competitors to GWHP include public companies such as Biomerica, Trinity Biotech, Quidel Corp., and a private company called Diagnostic Substances.

Competition in the development and marketing of in-vitro diagnostic real time polymerase chain reaction testing is intense with a high degree of innovation, product development, and hurdles such as regulatory clearance in order to market and commercialize new products. In this segment of the industry the most significant competitive factors are convenience, speed to results, specimen flexibility, product menu, clinical needs, price, reimbursement levels and product performance, as well as effective distribution. Some of the larger companies that compete in this space include Abbott Laboratories, Beckman Coulter Primary Care Diagnostics, Becton Dickinson, Meridian Bioscience, Inc., and Danaher Corporation.

### ***Risks***

In our view, these are the principal risks underlying the stock.

#### **Operating Losses – Going Concern**

Global WholeHealth Partners Corp. just began generating revenue of \$242,000 and \$15,000 in 4Q20 and 1Q21, respectively. In 1Q21, the company's accumulated deficit was \$5 million, up from \$4.7 million in FY20 (year-ended June 30, 2020). The lack of sustained revenue and operating profits could result in the company's inability to execute its growth strategy and diminish its operations. The company's ability to continue as a going concern will depend upon the availability and terms of future funding, generating sales and profits. If GWHP is unable to achieve these goals, its business could be jeopardized and may not be able to continue.

#### **Dilution**

The company's capital requirements are likely to be significant, since it is beginning the process of developing sales channels and marketing of its products. If sufficient funding is not obtained, Global WholeHealth Partners may not be able to fully implement its growth plans.

On July 22, 2020, Global WholeHealth Partners entered into a common stock purchase agreement and a registration rights agreement with EMC2 Capital, LLC. EMC2 Capital agreed to invest up to \$100 million to purchase GWHP common stock. A common stock purchase warrant agreement was entered into for a purchase from the company of up to 2 million shares of the company's common stock. Terms and timing have not been disclosed.

#### Global Pandemic

The COVID-19 global pandemic or any future outbreaks of contagious diseases could have a material adverse effect on Global WholeHealth Partners internal operations. The COVID-19 pandemic has impacted US economic activity, as well as the internal operations of companies. The impact on companies include, but are not limited to, disruptions or restrictions on employees ability to work effectively due to illness, travel bans, quarantines, shelter-in-place orders or other limitations such as in person sales calls.

#### COVID-19 Vaccine

If a COVID-19 vaccine is developed, manufactured, and distributed in the US, it could cause a temporary near term pause in rapid diagnostic and real time polymerase chain reaction tests, which could disrupt potential sales. However, the need for those tests is likely to remain significant until a significant portion of the US and global population is vaccinated for COVID-19.

#### Market Acceptance

In order to obtain significant sales volume, the company's products must not only be approved by regulators, but also be endorsed by the in-vitro diagnostics industry. Therefore, success depends on GWHP's testing ability to accurately identify disease in a cost effective manner. There is no assurance that the company's tests will receive market acceptance.

#### Corporate Infrastructure

The company has limited sales and marketing infrastructure and accordingly the CEO is working with a commissioned sales team and distributors of medical tests. At September 30, 2020, no full time personnel was working for the company, therefore to achieve commercial success for any product for that has obtained marketing approval, the establishment of a sales and marketing infrastructure or out-license program will be necessary.

If the company chooses to build an internal sales and marketing infrastructure to sell its offerings, there are numerous potential complications, including funding, recruiting, and training professionals.

In FY20, the company's CEO devoted approximately 30 hours per week to the operations along with the use of independent contractors.

#### Partners

Global WholeHealth Partners has partnered with four suppliers and contract manufactures that will make approximately 80% of its tests. The plan is for each manufacturer to cover approximately 20% of the products marketed by the company and for the remaining 20% to be manufactured by Dr. Shujie Cui at his facility in San Diego. Dr. Shujie Cui is the company's Chief Science Officer. If one or all of the company's manufacturing partners is unable to produce its offering, the San Diego facility is likely to have the ability to pick up the slack. However, a shift to the San Diego facility would likely cause a significant delay in shipping and cause a material adverse effect on the company's ability to generate revenue.

If any of the company's supplier partners fail to comply with FDA Current Good Manufacturing Practices, new partners would need to be found, resulting in negative impacts on operations.

#### Regulatory Approvals

GWHP is subject to extensive national, state and local government regulation. Success will depend on the ability to obtain regulatory approvals in US and countries outside of the US for its offerings. The company anticipates it is unlikely there will be any significant problems in obtaining future required licenses, permits or approvals that are necessary to expand operations. However, registration filings could take longer to be approved than expected that would cause a delay in obtaining regulatory approvals or might cause delay in starting operations in countries and/or

other jurisdictions. Even though the company can produce offerings that are FDA approved for sale, it will continue to work on obtaining offerings approved through the FDA 510K process.

Shareholder Control

Officers, directors, and 5% owners collectively own approximately 52.4% of the outstanding voting stock (September 2020 SEC Filing). Officers could potentially greatly influence the outcome of matters requiring stockholder approval. These decisions may or may not be in the best interests of the other shareholders.

Miscellaneous Risk

The company's financial results and equity values are subject to other risks and uncertainties, including competition, operations, financial markets, regulatory risk, and/or other events. These risks may cause actual results to differ from expected results.

Trading Volume

Liquidity is a potential concern. Over the last three months (ending November 30, 2020) average daily volume was approximately 84,000. GWHP has approximately 60 million shares outstanding and a float of approximately 28.6 million. Investors should be aware that a thinly traded equity could experience price volatility.

Global WholeHealth Partners Corp.  
Consolidated Balance Sheets – Ending June 30  
FY2018 – 1Q21A  
(in thousands)

|  | <u>FY18A</u>    | <u>FY19A</u> | <u>FY20A</u>   | <u>1Q21A</u>   |
|--|-----------------|--------------|----------------|----------------|
| <b>ASSETS</b>  |                 |              |                |                |
| Current assets:  |                 |              |                |                |
| Cash   | \$ -            | \$ 20        | \$ 14          | \$ 133         |
| Prepaid expenses   | -               | -            | 15             | 3              |
| Inventory  | -               | -            | <u>152</u>     | <u>215</u>     |
| <b>Total current assets</b>                                    | -               | 20           | 182            | 350            |
| Property and equipment, net                                    | -               | -            | -              | 3              |
| <b>Total assets</b>  | <u>\$ -</u>     | <u>\$ 20</u> | <u>\$ 182</u>  | <u>\$ 353</u>  |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>                    |                 |              |                |                |
| Current liabilities:   |                 |              |                |                |
| Accounts payable and accrued liabilities                       | 1,415           | 0            | 46             | 8              |
| Convertible notes payable, net                                 | -               | -            | 70             | 149            |
| Related party payables   | -               | -            | 4              | 2              |
| Related party note   | -               | -            | <u>121</u>     | <u>37</u>      |
| <b>Total current liabilities</b>                               | 1,415           | 0            | 241            | 196            |
| <b>Stockholders' equity:</b>                                   |                 |              |                |                |
| Common stock, \$.001 par value; authorized 400,000,000 shares; | 0               | 56           | 60             | 60             |
| Additional paid-in capital                                     | 431             | 427          | 4,629          | 4,753          |
| Common stock payable   | -               | -            | -              | 340            |
| Retained earnings (accumulated deficit)                        | <u>(432)</u>    | <u>(463)</u> | <u>(4,749)</u> | <u>(4,996)</u> |
| <b>Total stockholders' equity</b>                              | <u>(1)</u>      | <u>20</u>    | <u>(60)</u>    | <u>157</u>     |
| <b>Total liabilities and stockholders' equity</b>              | <u>\$ 1,414</u> | <u>\$ 20</u> | <u>\$ 182</u>  | <u>\$ 353</u>  |
| SHARES OUT   | 52              | 56,116       | 59,966         | 59,966         |

Source: Company reports

Global WholeHealth Partners Corp.  
Annual Income Statement – Ending June 30  
FY2018 – FY2020A  
(in thousands)

|                                     | <u>FY18 A</u>    | <u>FY19 A</u>    | <u>FY20 A</u>    |
|-------------------------------------|------------------|------------------|------------------|
| Revenue                             | \$ -             | \$ -             | \$ 242           |
| Cost of sales                       | <u>-</u>         | <u>-</u>         | <u>151</u>       |
| <b>Gross Profit</b>                 | <u>-</u>         | <u>-</u>         | <u>91</u>        |
| <b>Operating Expenses:</b>          |                  |                  |                  |
| Management fees                     | -                | 24               | -                |
| Professional fees                   | 1                | 10               | 62               |
| Research and development            |                  | -                | 513              |
| Selling, general and administrative |                  | -                | 3,782            |
| Bank fees                           | -                | 0                | -                |
| Total Operating Expenses            | <u>1</u>         | <u>34</u>        | <u>4,357</u>     |
| <b>Operating Income (loss)</b>      | (1)              | (34)             | (4,266)          |
| Interest expense                    | -                | -                | (3)              |
| Accretion of debt discount          | -                | -                | (17)             |
| Gain on Forgiveness of liabilities  | <u>-</u>         | <u>3</u>         | <u>-</u>         |
| Total Other Income (expense)        | <u>-</u>         | <u>3</u>         | <u>(20)</u>      |
| <b>Pre-Tax Income (loss)</b>        | (1)              | (31)             | (4,286)          |
| Income Tax Expense (Benefit)        | <u>-</u>         | <u>-</u>         | <u>-</u>         |
| Net income (loss)                   | <u>(1)</u>       | <u>(31)</u>      | <u>(4,286)</u>   |
| <b>Earning (loss) per share</b>     | <u>\$ (0.02)</u> | <u>\$ (0.01)</u> | <u>\$ (0.07)</u> |
| Avg Shares Outstanding              | 52               | 5,893            | 57,804           |
| Adjusted EBITDA                     | \$ (1)           | \$ (2)           | \$ (566)         |
| Margin Analysis                     |                  |                  |                  |
| Gross margin                        |                  |                  | 37.7%            |
| Professional fees                   |                  |                  | NMF              |
| Research and development            |                  |                  | NMF              |
| SG&A                                |                  |                  | NMF              |
| Operating margin                    |                  |                  | NMF              |
| Pre-tax margin                      |                  |                  | NMF              |

Source: Company reports

Global WholeHealth Partners Corp.  
Income Statement Model – Ending June 30  
Quarters FY2019A – 1Q21A  
(in thousands)

|   | Q1 19 A          | Q2 19 A          | Q3 19 A          | Q4 19 A          | FY19 A           | Q1 20 A          | Q2 20 A          | Q3 20 A          | Q4 20 A          | FY20 A           | Q1 21 A          |
|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Revenue   | \$ -             | \$ -             | \$ -             | \$ -             | \$ -             | \$ -             | \$ -             | \$ -             | \$ 242           | \$ 242           | \$ 15            |
| Cost of sales   | -                | -                | -                | -                | -                | -                | -                | -                | 151              | 151              | 11               |
| <b>Gross Profit</b>   | -                | -                | -                | -                | -                | -                | -                | -                | 91               | 91               | 5                |
| <b>Operating Expenses:</b>                                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Management fees   | -                | -                | -                | 24               | 24               | -                | -                | -                | -                | -                | -                |
| Professional fees   | 1                | -                | 7                | 2                | 10               | 15               | 21               | 9                | 17               | 62               | 34               |
| Research and development including related party            | -                | -                | -                | -                | -                | -                | -                | 444              | 69               | 513              | 139              |
| Selling, general and administrative including related party | -                | 0                | 2                | (3)              | -                | 4                | 30               | 3                | 3,745            | 3,782            | 33               |
| Bank fees   | -                | -                | -                | 0                | 0                | -                | -                | -                | -                | -                | -                |
| Total Operating Expenses                                    | 1                | 0                | 9                | 23               | 34               | 19               | 51               | 455              | 3,831            | 4,357            | 206              |
| <b>Operating Income (loss)</b>                              | (1)              | (0)              | (9)              | (23)             | (34)             | (19)             | (51)             | (455)            | (3,740)          | (4,266)          | (201)            |
| Interest expense  | -                | -                | -                | -                | -                | -                | -                | -                | (3)              | (3)              | (5)              |
| Accretion of debt discount                                  | -                | -                | -                | -                | -                | -                | -                | -                | (17)             | (17)             | (41)             |
| Gain on Forgiveness of liabilities                          | -                | -                | -                | 3                | 3                | -                | -                | 444              | (444)            | -                | -                |
| Total Other Income (expense)                                | -                | -                | -                | 3                | 3                | -                | -                | 444              | (464)            | (20)             | (46)             |
| <b>Pre-Tax Income (loss)</b>                                | (1)              | (0)              | (9)              | (20)             | (31)             | (19)             | (51)             | (12)             | (4,204)          | (4,286)          | (247)            |
| Income Tax Expense (Benefit)                                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Net income (loss)   | (1)              | (0)              | (9)              | (20)             | (31)             | (19)             | (51)             | (12)             | (4,204)          | (4,286)          | (247)            |
| <b>Earning (loss) per share</b>                             | <u>\$ (0.02)</u> | <u>\$ (0.01)</u> | <u>\$ (0.17)</u> | <u>\$ (0.00)</u> | <u>\$ (0.01)</u> | <u>\$ (0.00)</u> | <u>\$ (0.00)</u> | <u>\$ (0.00)</u> | <u>\$ (0.07)</u> | <u>\$ (0.07)</u> | <u>\$ (0.00)</u> |
| Avg Shares Outstanding                                      | 52               | 52               | 52               | 5,893            | 5,893            | 56,116           | 57,804           | 58,116           | 59,180           | 57,804           | 59,980           |
| Adjusted EBITDA   | \$ (1)           | \$ (0)           | \$ (9)           | \$ 9             | \$ (2)           | \$ (19)          | \$ (51)          | \$ (455)         | \$ (40)          | \$ (566)         | \$ (201)         |
| Margin Analysis   |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Gross margin  |                  |                  |                  |                  |                  |                  |                  |                  | 37.7%            | 37.7%            | 31.5%            |


Source: Company reports

Trxade Group, Inc.  
Cash Flow Statement – Ending June 30  
FY2017 – 1Q21A  
(in thousands)


|  | <u>FY2018A</u> | <u>FY2019A</u> | <u>FY2020A</u> | <u>1Q21A</u>  |
|--|----------------|----------------|----------------|---------------|
| <i>Cash Flows from Operating Activities</i>  |                |                |                |               |
| Net Income (loss)                            | \$ (1)         | \$ (31)        | \$ (4,286)     | \$ (247)      |
| Depreciation                                 | -              | -              | -              | 0             |
| Common stock issued for services             | -              | 24             | 3,700          | -             |
| Accretion of debt discount                   | -              | -              | 17             | 41            |
| Common stock issued for debt settlement      | -              | 8              | -              | -             |
| Cash earnings (burn)                         | <u>(1)</u>     | <u>1</u>       | <u>(568)</u>   | <u>(206)</u>  |
| <i>Changes In:</i>                           |                |                |                |               |
| Prepaid expenses and other assets            | -              | -              | (15)           | 13            |
| Inventory                                    | -              | -              | (152)          | (62)          |
| Related party payables                       | -              | -              | 4              | (1)           |
| Accounts payable and accrued expenses        | <u>1</u>       | <u>(1)</u>     | <u>46</u>      | <u>(38)</u>   |
| (Increase)/decrease in Working Capital       | <u>1</u>       | <u>(1)</u>     | <u>(117)</u>   | <u>(89)</u>   |
| <b>Net cash provided by Operations</b>       | <u>-</u>       | <u>(0)</u>     | <u>(685)</u>   | <u>(295)</u>  |
| <i>Cash Flows from Investing Activities</i>  |                |                |                |               |
| Purchase of equipment                        | <u>-</u>       | <u>-</u>       | <u>-</u>       | <u>(4)</u>    |
| <b>Cash Flows from Investing Activities</b>  | <u>-</u>       | <u>-</u>       | <u>-</u>       | <u>(4)</u>    |
| <i>Cash Flows from Financing Activities</i>  |                |                |                |               |
| Cash for common shares of stock              | -              | 20             | 20             | 340           |
| Repayment of related party note              | -              | -              | -              | (110)         |
| Proceeds from related party note, net        | -              | -              | 121            | 24            |
| Proceeds from convertible notes              | -              | -              | 95             | 162           |
| Proceeds from related party advances         | <u>-</u>       | <u>-</u>       | <u>444</u>     | <u>-</u>      |
| <b>Net cash provided (used) by Financing</b> | <u>-</u>       | <u>20</u>      | <u>680</u>     | <u>416</u>    |
| Net change in Cash and restricted cash       | -              | 20             | (5)            | 118           |
| Cash and restricted cash Beginning of Period | <u>-</u>       | <u>-</u>       | <u>20</u>      | <u>14</u>     |
| Cash (and restricted) End of Period          | <u>\$ -</u>    | <u>\$ 20</u>   | <u>\$ 14</u>   | <u>\$ 133</u> |

Source: Company reports

**Price Chart**



**Taglich Brothers Current Ratings Distribution**



| <b>Investment Banking Services for Companies Covered in the Past 12 Months</b> |          |          |
|--|----------|----------|
| <u>Rating</u>  | <u>#</u> | <u>%</u> |
| Buy  | 3        | 15       |
| Hold   |          |          |
| Sell   |          |          |
| Not Rated  |          |          |

**Important Disclosures**

As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned in this report. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company with in the last three years.

All research issued by Taglich Brothers, Inc. is based on public information. In July 2020, the company paid Taglich Brothers a monetary fee of \$6,000 (USD) representing payment for the creation and dissemination of research reports for three months. Three months after publication of the initial report (February 2021), the company will begin paying Taglich Brothers a monthly monetary fee of \$2,000 (USD) for the creation and dissemination of research reports.

**General Disclosures**

The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance.

**Analyst Certification**

**I, Howard Halpern, the research analyst of this report, hereby certify that the views expressed in this report accurately reflect my personal views about the subject securities and issuers; and that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report.**

**Public Companies mentioned in this report:**

|                     |                |                     |                |
|---------------------|----------------|---------------------|----------------|
| Abbott Laboratories | (NYSE: ABT)    | Becton Dickinson    | (NYSE: BDX)    |
| Danaher Corporation | (NYSE: DHR)    | Johnson & Johnson   | (NYSE: JND)    |
| Quidel Corporation  | (NASDAQ: QDEL) | Trinity Biotech plc | (NASDAQ: TRIB) |

### **Meaning of Ratings**

**Buy** – The growth prospects, degree of investment risk, and valuation make the stock attractive relative to the general market or comparable stocks.

**Speculative Buy** – Long-term prospects of the company are promising but investment risk is significantly higher than it is in our BUY-rated stocks. Risk-reward considerations justify purchase mainly by high risk-tolerant accounts. In the short run, the stock may be subject to high volatility and could continue to trade at a discount to its market.

**Neutral** – Based on our outlook the stock is adequately valued. If investment risks are within acceptable parameters, this equity could remain a holding if already owned.

**Sell** – Based on our outlook the stock is significantly overvalued. A weak company or sector outlook and a high degree of investment risk make it likely that the stock will underperform relative to the general market.

**Discontinued** – Research coverage discontinued due to the acquisition of the company, termination of research services (includes non-payment for such services), diminished investor interest, or departure of the analyst.

### **Some notable Risks within the Microcap Market**

**Stocks in the Microcap segment of the market have many risks that are not as prevalent in Large-cap, Blue Chips or even Small-cap stocks. Often it is these risks that cause Microcap stocks to trade at discounts to their peers. The most common of these risks is liquidity risk, which is typically caused by small trading floats and very low trading volume which can lead to large spreads and high volatility in stock price. In addition, Microcaps tend to have significant company-specific risks that contribute to lower valuations. Investors need to be aware of the higher probability of financial default and higher degree of financial distress inherent in the microcap segment of the market.**

---

From time to time our analysts may choose to withhold or suspend a rating on a company. We continue to publish informational reports on such companies; however, they have no ratings or price targets. In general, we will not rate any company that has too much business or financial uncertainty for our analysts to form an investment conclusion, or that is currently in the process of being acquired.